

ASX Announcement

Strategic Collaboration with Eureka Therapeutics to Accelerate Advancement of Oncolytic Virus and T-Cell Therapy in Solid Tumours (supplementary announcement)

Sydney, Australia, November 9, 2021

Further to the announcement of the strategic collaboration with Eureka Therapeutics released on 1 November 2021, at the request of the ASX, Imugene Ltd (“Imugene”) (ASX: IMU), a clinical stage immuno-oncology company, provides additional information regarding the strategic collaboration with Eureka Therapeutics, Inc. (“Eureka”), a clinical-stage biotechnology company developing novel T-cell therapies to treat solid tumours.

The strategic collaboration is effective immediately and will continue whilst there are relevant research activities being performed under the research plan. The research plan will be reviewed approximately every six months by the Joint Steering Committee. The strategic collaboration may be terminated upon completion of the research activities, by agreement, or according to common commercial termination provisions. Imugene will fund its component of the strategic collaboration by accelerating its existing planned research activities and aligning activities to milestones agreed by the Joint Steering Committee. No additional or new funding is required for the initial activities by Imugene for the strategic collaboration. The funding of Imugene research activities is material and is allowed for in the Company’s existing research budget.

Each party has full intellectual property (IP) rights (patents) to their individual background technology. In the event new IP is generated from the strategic collaboration (each a “Joint Collaboration Technology”), the parties shall discuss in good faith the filing, prosecution, maintenance, enforcement, defense of any patent applications relating thereto, as well as each party’s right to use, such Joint Collaboration Technology.

After the results from this research agreement are known and can be quantified, the parties will negotiate in good faith (and without obligation) whether to jointly develop or commercialise on the outcomes of the strategic collaboration on commercially reasonable terms.

For more information please contact:

Leslie Chong
Managing Director and Chief Executive Officer
info@imugene.com
Investor Enquiries
investor@imugene.com

Media Enquiries
Matt Wright
matt@nwrcommunications.com.au

Follow us on Twitter @TeamImugene
Like us on Facebook @Imugene
Connect with us on LinkedIn @Imugene Limited

Eureka Therapeutics, Inc.
Natalie Liu
Investor Relations
510-318-9215
IR@eurekainc.com

About Eureka Therapeutics, Inc.

Eureka Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel cancer T-cell therapies to treat cancers. The company is developing potentially safer and more effective T cell therapies for the treatment of solid tumors and hematologic malignancies using its ARTEMIS® cell receptor platform and E-ALPHA® antibody discovery platform. ET140203 and ECT204, the company's lead assets, are currently in Phase I/II US multi-center clinical trials in patients with advanced hepatocellular carcinoma (HCC), the most common form of liver cancer. Eureka is headquartered in the San Francisco Bay Area. For more information, please visit: www.eurekatherapeutics.com. Follow us on Twitter at [@EurekaThera](https://twitter.com/EurekaThera).

About Oncolytic Virus Technology

Researchers first created an oncolytic virus (CF33-CD19) in the lab of City of Hope's Yuman Fong, M.D., to get into tumour cells and start producing CD19. They did this successfully in triple-negative breast, pancreatic, prostate, ovarian, head and neck, and brain cancer cell lines. CF33-CD19 oncolytic virus was then combined with CD19 CAR T cells in vitro and in vivo mice studies. Researchers showed significant activity with mice being cured of their cancer with the CF33-CD19 and CAR T-cell combination, as well as prolonged protective anti-tumour immunity. Solid tumours don't express CD19

on their cell surface, therefore introducing the CF33-CD19 allowed for CD19 to be present on the solid tumour cell surface, as well as helped to reverse the tumour's harsh microenvironment, making it receptive to receiving CAR T-cell therapy. The first clinical trial is anticipated to start in 2022 and will evaluate the safety and efficacy of CF33-CD19 in combination with CAR T therapy in patients with solid tumours.

About Imugene (ASX: IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Managing Director and Chief Executive Officer

Imugene Limited, Level 3, 62 Lygon Street, Carlton, VIC, 3053, Australia